Swiss recommendations for adult cystic fibrosis care

PREFACE

DISCLAIMER

ADVISORY BOARD

AUTHORS AND EXPERT REVIEWERS

SPONSORS

1. PATHOGENESIS OF CYSTIC FIBROSIS

2. DIAGNOSIS IN ADULTS

3. TRANSITION FROM PEDIATRIC TO ADULT CARE

4. PULMONARY DISEASE  

4.1 CLINICAL EVALUATION

4.2 GENERAL MANAGEMENT 

     4.2.1 Physiotherapy

     4.2.2 Medications

     4.2.3 Therapeutic drug monitoring

     4.2.4 Antibiotic allergy

     4.2.5 Venous access

     4.2.6 Vaccination

4.3 INFECTIONS

     4.3.1 Infection control

     4.3.2 Staphylococcus aureus

     4.3.3 Pseudomonas aeruginosa

     4.3.4 Burkholderia cepacia complex

     4.3.5 Other relevant bacteria

     4.3.6 Non-tuberculous mycobacteria

     4.3.7 Fungi

     4.3.8 Viruses

4.4 ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS (ABPA)

4.5 ASTHMA AND RESPIRATORY ALLERGY

4.6 SMALL AIRWAYS DISEASE

4.7 HEMOPTYSIS

4.8 PNEUMOTHORAX

4.9 PULMONARY HYPERTENSION

4.10 OXYGEN THERAPY AND NON-INVASIVE VENTILATION

4.11 ICU CARE AND INVASIVE VENTILATION

5. EAR, NOSE AND THROAT DISEASE

6. GASTROINTESTINAL DISEASE AND NUTRITION

6.1 CLINICAL EVALUATION

6.2 PANCREATIC DISEASE

     6.2.1 Exocrine pancreatic insufficiency

     6.2.2 Pancreatitis

6.3 HEPATOBILIARY DISEASES

6.4 GASTRO-OESOPHAGEAL REFLUX

6.5 INTESTINAL OBSTRUCTION SYNDROMES

6.6 INFLAMMATORY BOWEL DISEASE

6.7 NUTRITION

7. CYSTIC-FIBROSIS RELATED DIABETES

8. BONE DISEASE

9. CYSTIC FIBROSIS-RELATED ARTHROPATHIES

10. RENAL DISEASE

11. URINARY DISEASE

12. FERTILITY AND PREGANCNY

13. SAFETY OF MEDICATION USE
DURING PREGNANCY AND BREASTFEEDING

14. PSYCHOLOGICAL ISSUES

15. TRAVELLING, ALTITUDE AND DIVING

16. CYSTIC FIBROSIS AND AGING

17. CFTR MODIFIERS

18. TRANSPLANTATION

19. PALLIATIVE AND END-OF-LIFE CARE

20. ANNUAL ASSESSMENT

21. CYSTIC FIBROSIS REGISTRY

22. ADMINISTRATIVE INFORMATION

23. ASSOCIATIONS AND FOUNDATIONS